Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche
Sara Chiblak, Zili Tang, Dieter Lemke, Maximilian Knoll, Ivana Dokic, Rolf Warta, Mahmoud Moustafa, Walter Mier, Stephan Brons, Carmen Rapp, Stefan Muschal, Philipp Seidel, Martin Bendszus, Sebastian Adeberg, Otmar D. Wiestler, Uwe Haberkorn, Jürgen Debus, Christel Herold-Mende, Wolfgang Wick, Amir Abdollahi
Sara Chiblak, Zili Tang, Dieter Lemke, Maximilian Knoll, Ivana Dokic, Rolf Warta, Mahmoud Moustafa, Walter Mier, Stephan Brons, Carmen Rapp, Stefan Muschal, Philipp Seidel, Martin Bendszus, Sebastian Adeberg, Otmar D. Wiestler, Uwe Haberkorn, Jürgen Debus, Christel Herold-Mende, Wolfgang Wick, Amir Abdollahi
View: Text | PDF
Research Article Oncology Therapeutics

Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche

  • Text
  • PDF
Abstract

Tumor radioresistance leading to local therapy failure remains a major obstacle for successful treatment of high-grade glioma. We hypothesized that distinct radiobiological features of particle therapy with carbon ions may circumvent glioma radioresistance. We demonstrate that carbon irradiation (CIR) efficiently eradicates radioresistant patient-derived glioma stem cells (GSCs), leading to growth inhibition and prolonged survival. The impact of CIR at the tumor–stroma interface was further investigated in 2 syngeneic mouse and 2 orthotopic GSC xenograft models. Intriguingly, tumor regressions and long-term local controls were observed at doses greater than or equal to 15-Gy CIR. Fractionated CIR further prolonged survival. The enhanced relative biological effectiveness of CIR in vivo was attributed to its potent antiangiogenic effects and eradication of radioresistant hypoxic tumor cells. Blockade of the HIF1-α/stromal cell–derived factor 1/CXCR4 axis by CIR reduced the recruitment of microglia and myeloid-derived suppressor cells (CD11b+Gr1+). Consequently, CIR abrogated M2-like immune polarization and enhanced the influx of CD8+ cells, generating an immunopermissive niche. We report that radiotherapy with carbon ions could surmount several central glioma resistance mechanisms by eradicating hypoxic and stem cell–like tumor cells, as well as modulating the glioma niche toward an antiangiogenic and less immunosuppressive state. Conclusively, potentially novel rationales for CIR in conquering glioma radioresistance are provided.

Authors

Sara Chiblak, Zili Tang, Dieter Lemke, Maximilian Knoll, Ivana Dokic, Rolf Warta, Mahmoud Moustafa, Walter Mier, Stephan Brons, Carmen Rapp, Stefan Muschal, Philipp Seidel, Martin Bendszus, Sebastian Adeberg, Otmar D. Wiestler, Uwe Haberkorn, Jürgen Debus, Christel Herold-Mende, Wolfgang Wick, Amir Abdollahi

×

Figure 1

Effect of CIR on patient-derived, GSC-enriched xenograft models.

Options: View larger image (or click on image) Download as PowerPoint
Effect of CIR on patient-derived, GSC-enriched xenograft models.
Establi...
Establishment of small animal CIR in orthotopic glioma models. (A) Verification of administered dose by overlay of CIR-induced secondary positrons (C11 micro-PET, black) and tumor uptake of 18F-fluoro-ethyl-tyrosine (FET) PET, circled in red at the intersection of the horizontal and vertical lines, indicating precision treatment. (B) Significant inhibition of tumor growth after CIR (5 × 1.5 Gy) versus PIR (5 × 5 Gy) and sham-treated control in an orthotopic xenograft model derived from patient NCH441 GSCs (n = 3). Tumor growth was monitored longitudinally by bioluminescence (see also supplemental material). Ctrl: control. (C) CIR (6 Gy, n = 10) significantly prolonged animal survival compared with PIR (15 Gy, n = 10), both administered in 3 consecutive daily fractions in the NCH644 GSC model. Kaplan-Meier survival estimates and tumor growth kinetic via MRI-based tumor volumetry are shown. (D and E) PIR (n = 5) led to a relative enrichment of the GSC population compared with control (n = 3) and CIR (n = 5) as determined by NCH644 tumor I131α-CD133 uptake ratio and biodistribution studies (supplemental material). The lack of selection for α-CD133+ GSCs (red) is also elucidated by representative immunofluorescence staining. Nuclei counterstained using DAPI (blue). Box and whisker plots represent median, interquartile, minimum, and maximum of all data points. §P < 0.0001, *P < 0.05 versus control, when shown over a box, or versus the indicated irradiation treatment. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts